Home LiteratureArticle Details
PMID: 21866433 Published · ppublish English Journal Article Review

Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

European radiology ·Vol. 21 ·No. 12 ·2011-12-00 ·Pages 2527-41

Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almén T, Aspelin P, Bellin MF, Clement O, Heinz-Peer G, Contrast Media Safety Committee of European Society of Urogenital Radiology ESUR

Abstract

The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) has updated its 1999 guidelines on contrast medium-induced nephropathy (CIN). Topics reviewed include the definition of CIN, the choice of contrast medium, the prophylactic measures used to reduce the incidence of CIN, and the management of patients receiving metformin. Key Points • Definition, risk factors and prevention of contrast medium induced nephropathy are reviewed. • CIN risk is lower with intravenous than intra-arterial iodinated contrast medium. • eGFR of 45 ml/min/1.73 m (2) is CIN risk threshold for intravenous contrast medium. • Hydration with either saline or sodium bicarbonate reduces CIN incidence. • Patients with eGFR ≥ 60 ml/min/1.73 m (2) receiving contrast medium can continue metformin normally.

MeSH Terms
Contrast Media/administration & dosage,adverse effects Coronary Angiography/adverse effects,methods Europe Female Fluid Therapy Gadolinium/administration & dosage,adverse effects Glomerular Filtration Rate Heart Failure/diagnostic imaging Humans Injections, Intra-Arterial Injections, Intravenous Iodine/administration & dosage,adverse effects Male Practice Guidelines as Topic Renal Insufficiency/chemically induced,physiopathology,prevention & control Risk Factors Sodium Bicarbonate/administration & dosage Sodium Chloride/administration & dosage
Chemicals
Contrast Media Sodium Chloride Sodium Bicarbonate Iodine Gadolinium
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Stacul Fulvio
S.C. Radiologia Ospedale Maggiore, Piazza Ospitale 1, 34134 Tieste, Italy.
van der Molen Aart J
Reimer Peter
Webb Judith A W
Thomsen Henrik S
Morcos Sameh K
Almén Torsten
Aspelin Peter
Bellin Marie-France
Clement Olivier
Heinz-Peer Gertraud
Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)
Investigators
14 investigators, click to expand
Thomsen H S
Morcos S K
Almén T
Aspelin P
Bellin M F
Clement O
Heinz-Peer G
Reimer P
Stacul F
van der Molen A J
Webb J A W
Ideé J-M
Lengfeld P
Spinazzi A
References (153)
153 references, click to expand
  1. Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components.
    Nephrol Dial Transplant. 2007 Sep;22(9):2728-9 PMID: 17567651
  2. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.
    Radiology. 2010 Jan;254(1):261-9 PMID: 20032157
  3. Prevention of contrast-induced nephropathy: an overview.
    Radiol Clin North Am. 2009 Sep;47(5):801-11, v PMID: 19744595
  4. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures.
    Catheter Cardiovasc Interv. 2006 Feb;67(2):175-80 PMID: 16400668
  5. Prevention of contrast-induced nephropathy: a critical review.
    Curr Opin Nephrol Hypertens. 2007 Jul;16(4):336-47 PMID: 17565276
  6. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
    J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9 PMID: 15464318
  7. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity.
    AJR Am J Roentgenol. 2008 Aug;191(2):376-82 PMID: 18647905
  8. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
    Circulation. 2009 Nov 3;120(18):1793-9 PMID: 19841299
  9. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction.
    Chest. 1998 Dec;114(6):1570-4 PMID: 9872190
  10. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.
    J Vasc Surg. 2003 Aug;38(2):313-8 PMID: 12891113
  11. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis.
    Am Heart J. 2008 Sep;156(3):414-21 PMID: 18760120
  12. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
    Kidney Int. 2005 Nov;68(5):2250-5 PMID: 16221226
  13. Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies.
    Eur Radiol. 2011 Jan;21(1):63-9 PMID: 20680288
  14. Metformin and contrast media.
    Radiology. 2010 Aug;256(2):672-3; author reply 673 PMID: 20656850
  15. Improving outcomes of acute kidney injury: report of an initiative.
    Nat Clin Pract Nephrol. 2007 Aug;3(8):439-42 PMID: 17653122
  16. Gadolinium-containing contrast media for radiographic examinations: a position paper.
    Eur Radiol. 2002 Oct;12(10):2600-5 PMID: 12271402
  17. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.
    Circ Cardiovasc Interv. 2009 Oct;2(5):430-7 PMID: 20031753
  18. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing.
    Diabet Med. 2007 Oct;24(10):1160-3 PMID: 17672860
  19. Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings?
    J Nephrol. 2009 May-Jun;22(3):333-51 PMID: 19557710
  20. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability.
    Pharmacol Res. 1994 Oct-Nov;30(3):187-228 PMID: 7862618
  21. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis.
    Clin J Am Soc Nephrol. 2009 Oct;4(10):1584-92 PMID: 19713291
  22. Risk markers for contrast-induced nephropathy.
    Am J Med Sci. 2007 Oct;334(4):283-90 PMID: 18030185
  23. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure.
    Am J Cardiol. 2009 Oct 1;104(7):921-5 PMID: 19766757
  24. An overview of drug-induced acute kidney injury.
    Crit Care Med. 2008 Apr;36(4 Suppl):S216-23 PMID: 18382197
  25. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function.
    Radiology. 2008 Jul;248(1):97-105 PMID: 18483232
  26. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.
    Arch Intern Med. 2002 Feb 11;162(3):329-36 PMID: 11822926
  27. Kidney function and age are both predictors of pharmacokinetics of metformin.
    J Clin Pharmacol. 1995 Nov;35(11):1094-102 PMID: 8626883
  28. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction.
    Clin Nephrol. 2007 Nov;68(5):279-86 PMID: 18044259
  29. Creatinine kinetics and the definition of acute kidney injury.
    J Am Soc Nephrol. 2009 Mar;20(3):672-9 PMID: 19244578
  30. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.
    Am J Med. 1997 Nov;103(5):368-75 PMID: 9375704
  31. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis.
    Nephrol Dial Transplant. 2004 Nov;19(11):2747-53 PMID: 15328384
  32. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
    Am Heart J. 2004 Sep;148(3):422-9 PMID: 15389228
  33. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
    Circulation. 2007 Mar 13;115(10):1211-7 PMID: 17309916
  34. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    JACC Cardiovasc Interv. 2009 May;2(5):415-21 PMID: 19463464
  35. In which patients should serum creatinine be measured before iodinated contrast medium administration?
    Eur Radiol. 2005 Apr;15(4):749-54 PMID: 15627181
  36. Background fluctuation of kidney function versus contrast-induced nephrotoxicity.
    AJR Am J Roentgenol. 2009 Mar;192(3):711-8 PMID: 19234268
  37. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience.
    Mayo Clin Proc. 1996 Dec;71(12):1150-4 PMID: 8945485
  38. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy.
    Am J Med. 2009 Sep;122(9):874.e9-15 PMID: 19699385
  39. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography.
    J Am Soc Nephrol. 2006 Oct;17(10):2871-7 PMID: 16928802
  40. Incidence of lactic acidosis in metformin users.
    Diabetes Care. 1999 Jun;22(6):925-7 PMID: 10372243
  41. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients.
    Am J Med. 2006 Feb;119(2):155-62 PMID: 16443418
  42. Contrast-induced nephropathy after intravenous administration: fact or fiction?
    Radiol Clin North Am. 2009 Sep;47(5):789-800, v PMID: 19744594
  43. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study.
    Kidney Int. 1995 Jan;47(1):254-61 PMID: 7731155
  44. Evidence-based emergency medicine review. Prevention of contrast-induced nephropathy in the emergency department.
    Ann Emerg Med. 2007 Sep;50(3):335-45, 345.e1-2 PMID: 17512638
  45. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity.
    Eur Heart J. 2004 Feb;25(3):206-11 PMID: 14972420
  46. Prevention of contrast-induced nephropathy with volume expansion.
    Clin J Am Soc Nephrol. 2008 Jan;3(1):273-80 PMID: 17989201
  47. Contrast-induced nephropathy.
    Crit Care Clin. 2005 Apr;21(2):261-80 PMID: 15781162
  48. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.
    J Am Coll Cardiol. 2006 Aug 15;48(4):692-9 PMID: 16904536
  49. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary.
    Rev Cardiovasc Med. 2006 Fall;7(4):177-97 PMID: 17224862
  50. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.
    Am J Cardiol. 2005 Jan 1;95(1):13-9 PMID: 15619387
  51. Contraindications can damage your health--is metformin a case in point?
    Diabetologia. 2005 Dec;48(12):2454-9 PMID: 16283245
  52. What is the best definition of contrast-induced nephropathy?
    Ren Fail. 2007;29(3):387-8 PMID: 17497458
  53. N-Acetylcysteine does not artifactually lower plasma creatinine concentration.
    Nephrol Dial Transplant. 2008 May;23(5):1581-7 PMID: 18202091
  54. Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials.
    Clin Nephrol. 2010 Oct;74(4):288-96 PMID: 20875381
  55. Acetylcysteine and contrast agent-associated nephrotoxicity.
    J Am Coll Cardiol. 2002 Jul 17;40(2):298-303 PMID: 12106935
  56. The safety of gadolinium in patients with stage 3 and 4 renal failure.
    Nephrol Dial Transplant. 2006 Mar;21(3):697-700 PMID: 16326736
  57. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
    Invest Radiol. 2008 Mar;43(3):170-8 PMID: 18301313
  58. Multiple myeloma and contrast media.
    Radiology. 1992 May;183(2):519-21 PMID: 1561361
  59. Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin.
    Diabet Med. 2007 May;24(5):494-7 PMID: 17367305
  60. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence.
    Arch Intern Med. 2006 Jan 23;166(2):161-6 PMID: 16432083
  61. Nephrotoxic effects in high-risk patients undergoing angiography.
    N Engl J Med. 2003 Feb 6;348(6):491-9 PMID: 12571256
  62. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Catheter Cardiovasc Interv. 2008 Dec 1;72(7):958-65 PMID: 19021282
  63. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study.
    Radiology. 2001 Mar;218(3):651-7 PMID: 11230635
  64. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    J Am Coll Cardiol. 2006 Sep 5;48(5):924-30 PMID: 16949481
  65. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study.
    Diabetes Care. 2005 Mar;28(3):539-43 PMID: 15735184
  66. Gadolinium contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs.
    Acad Radiol. 2004 Nov;11(11):1219-28 PMID: 15561568
  67. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
    Am J Cardiol. 2008 Feb 1;101(3):279-85 PMID: 18237585
  68. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis.
    Wien Klin Wochenschr. 2008;120(23-24):742-8 PMID: 19122985
  69. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention.
    J Am Coll Cardiol. 2007 Aug 14;50(7):584-90 PMID: 17692741
  70. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media.
    Radiology. 1993 Jul;188(1):171-8 PMID: 8511292
  71. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Intern Med J. 2009 Jan;39(1):25-31 PMID: 18771430
  72. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
    AJR Am J Roentgenol. 2007 Sep;189(3):687-92 PMID: 17715118
  73. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial.
    Ann Intern Med. 1989 Jan 15;110(2):119-24 PMID: 2909204
  74. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.
    Am J Cardiol. 2004 Jun 15;93(12):1515-9 PMID: 15194023
  75. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.
    JAMA. 2004 May 19;291(19):2328-34 PMID: 15150204
  76. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable.
    J Am Soc Nephrol. 2004 Feb;15(2):407-10 PMID: 14747387
  77. Comparison of iodixanol and iohexol in renal impairment.
    Br J Radiol. 1999 Jul;72(859):701-3 PMID: 10624328
  78. Effectiveness of acetylcysteine in prevention of contrast nephropathy.
    J Invasive Cardiol. 2005 Feb;17(2):80-4 PMID: 15687530
  79. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.
    N Engl J Med. 2000 Jul 20;343(3):180-4 PMID: 10900277
  80. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients.
    Nephrol Dial Transplant. 2004 Oct;19(10):2526-31 PMID: 15280530
  81. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
    Am Heart J. 2008 Oct;156(4):776-82 PMID: 18946896
  82. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis.
    BMC Med. 2009 May 13;7:23 PMID: 19439062
  83. The global burden of chronic kidney disease: how valid are the estimates?
    Nephron Clin Pract. 2008;110(1):c39-46; discussion c47 PMID: 18689986
  84. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study.
    Am Heart J. 2008 Mar;155(3):499.e1-8 PMID: 18294484
  85. Improving outcomes from acute kidney injury.
    J Am Soc Nephrol. 2007 Jul;18(7):1992-4 PMID: 17596636
  86. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.
    Crit Care. 2007;11(2):R31 PMID: 17331245
  87. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee.
    Eur Radiol. 1999;9(4):738-40 PMID: 10354898
  88. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Circulation. 2007 Jun 26;115(25):3189-96 PMID: 17562951
  89. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses.
    Am Heart J. 2007 Feb;153(2):275-80 PMID: 17239689
  90. Estimated glomerular filtration rate: time for a performance review?
    Kidney Int. 2009 May;75(10):1001-3 PMID: 19404279
  91. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations.
    Eur J Intern Med. 2003 Nov;14(7):426-431 PMID: 14614975
  92. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.
    J Am Coll Cardiol. 2004 Nov 2;44(9):1780-5 PMID: 15519007
  93. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast.
    J Magn Reson Imaging. 1996 Jan-Feb;6(1):162-6 PMID: 8851422
  94. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency.
    J Am Coll Cardiol. 2000 Nov 1;36(5):1542-8 PMID: 11079656
  95. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention.
    Circulation. 2002 May 14;105(19):2259-64 PMID: 12010907
  96. Epidemiology of contrast-induced nephropathy.
    Rev Cardiovasc Med. 2003;4 Suppl 5:S3-9 PMID: 14668704
  97. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study.
    BMJ. 2006 Jan 28;332(7535):202-9 PMID: 16415336
  98. N-acetylcysteine in the prevention of contrast-induced nephropathy.
    Clin J Am Soc Nephrol. 2008 Jan;3(1):281-7 PMID: 18003766
  99. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
    Nephrol Dial Transplant. 2006 Aug;21(8):2120-6 PMID: 16611682
  100. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.
    Pediatrics. 1976 Aug;58(2):259-63 PMID: 951142
  101. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study.
    J Invasive Cardiol. 2003 Dec;15(12):699-702 PMID: 14660821
  102. Prevention of contrast media-induced nephrotoxicity after angiographic procedures.
    J Vasc Interv Radiol. 2005 Jan;16(1):13-23 PMID: 15640403
  103. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.
    Ann Intern Med. 2008 Feb 19;148(4):284-94 PMID: 18283206
  104. What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.
    Acta Radiol. 2008 Apr;49(3):310-20 PMID: 18365820
  105. Strategies to reduce the risk of contrast-induced nephropathy.
    Am J Cardiol. 2006 Sep 18;98(6A):59K-77K PMID: 16949381
  106. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Am Heart J. 2006 Jan;151(1):140-5 PMID: 16368307
  107. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.
    Nephron Clin Pract. 2003 Jan;93(1):C29-34 PMID: 12411756
  108. A new equation to estimate glomerular filtration rate.
    Ann Intern Med. 2009 May 5;150(9):604-12 PMID: 19414839
  109. Radiologists' knowledge and perceptions of the impact of contrast-induced nephropathy and its risk factors when performing computed tomography examinations: a survey of European radiologists.
    Eur J Radiol. 2008 May;66(2):235-45 PMID: 17728089
  110. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
    Invest Radiol. 2006 Nov;41(11):815-21 PMID: 17035872
  111. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002967 PMID: 20091535
  112. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures.
    Am Heart J. 2009 Nov;158(5):822-828.e3 PMID: 19853704
  113. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions.
    Kidney Int. 2005 Feb;67(2):706-13 PMID: 15673320
  114. Staging of chronic kidney disease: time for a course correction.
    J Am Soc Nephrol. 2008 May;19(5):844-6 PMID: 18385419
  115. Incidence and outcomes of contrast-induced AKI following computed tomography.
    Clin J Am Soc Nephrol. 2008 Sep;3(5):1274-81 PMID: 18463172
  116. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
    JAMA. 2003 Nov 5;290(17):2284-91 PMID: 14600187
  117. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
    Radiology. 2009 Jan;250(1):68-86 PMID: 19092091
  118. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
    Am J Kidney Dis. 2009 Oct;54(4):602-9 PMID: 19535188
  119. Contrast-induced nephropathy and long-term adverse events: cause and effect?
    Clin J Am Soc Nephrol. 2009 Jul;4(7):1162-9 PMID: 19556381
  120. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
    N Engl J Med. 2006 Jun 29;354(26):2773-82 PMID: 16807414
  121. The potential role of statins in contrast nephropathy.
    Clin Nephrol. 2004 Oct;62(4):273-8 PMID: 15524057
  122. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography.
    J Diabetes Complications. 2008 May-Jun;22(3):171-7 PMID: 18413220
  123. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography.
    Am J Med. 1990 Nov;89(5):615-20 PMID: 2239981
  124. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
    JAMA. 2003 Feb 5;289(5):553-8 PMID: 12578487
  125. Gadolinium-based contrast media may be nephrotoxic even at approved doses.
    Eur Radiol. 2004 Sep;14(9):1654-6 PMID: 15221265
  126. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.
    Eur Radiol. 2009 Apr;19(4):891-7 PMID: 19002467
  127. Dialysis and contrast media.
    Eur Radiol. 2002 Dec;12(12):3026-30 PMID: 12439587
  128. Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a quality improvement report.
    Am J Kidney Dis. 2010 Jun;55(6):1018-25 PMID: 20097462
  129. Metformin.
    N Engl J Med. 1996 Feb 29;334(9):574-9 PMID: 8569826
  130. Drug-induced nephrotoxicity.
    Am Fam Physician. 2008 Sep 15;78(6):743-50 PMID: 18819242
  131. Prophylaxis strategies for contrast-induced nephropathy.
    JAMA. 2006 Jun 21;295(23):2765-79 PMID: 16788132
  132. Are gadolinium-based contrast media nephrotoxic? A renal biopsy study.
    Arch Pathol Lab Med. 2006 Sep;130(9):1354-7 PMID: 16948524
  133. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration.
    N Engl J Med. 2003 Oct 2;349(14):1333-40 PMID: 14523141
  134. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial.
    Eur Radiol. 1998;8(1):144-7 PMID: 9442148
  135. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.
    Radiology. 2006 Jun;239(3):793-804 PMID: 16714461
  136. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?
    Clin Nephrol. 2004 Jul;62(1):1-7 PMID: 15267006
  137. Formula-based estimates of the GFR: equations variable and uncertain.
    Nephron Clin Pract. 2008;110(1):c48-53; discussion c54 PMID: 18708727
  138. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.
    Am J Kidney Dis. 2009 Apr;53(4):617-27 PMID: 19027212
  139. Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements.
    J Magn Reson Imaging. 2006 Mar;23(3):383-7 PMID: 16463306
  140. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions.
    Am J Med. 2005 Aug;118(8):843-9 PMID: 16084176
  141. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study.
    N Engl J Med. 1989 Jan 19;320(3):143-9 PMID: 2643041
  142. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
    Ann Intern Med. 2007 Sep 18;147(6):386-99 PMID: 17638715
  143. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.
    AJR Am J Roentgenol. 2008 Jul;191(1):151-7 PMID: 18562739
  144. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention.
    Acta Radiol. 2008 Jul;49(6):658-67 PMID: 18568558
  145. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR).
    Eur Radiol. 1999;9(8):1602-13 PMID: 10525875
  146. Use of intravenous contrast agents in patients receiving metformin.
    Radiology. 2002 Oct;225(1):311-2; author reply 312 PMID: 12355024
  147. Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function.
    Eur J Med Res. 2005 Apr 20;10(4):149-54 PMID: 15946910
  148. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
    Circulation. 2004 Nov 2;110(18):2837-42 PMID: 15492300
  149. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
    J Am Coll Cardiol. 2004 Aug 18;44(4):762-5 PMID: 15312855
  150. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    JACC Cardiovasc Interv. 2009 Jul;2(7):645-54 PMID: 19628188
  151. Serious renal dysfunction after percutaneous coronary interventions can be predicted.
    Am Heart J. 2008 Feb;155(2):260-6 PMID: 18215595
  152. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity.
    BMC Med. 2007 Nov 14;5:32 PMID: 18001477
  153. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
    Int J Cardiol. 2006 May 24;109(3):322-8 PMID: 16039733
Article Info
Journal
European radiology
Abbr.
Eur Radiol
ISSN
1432-1084
DOI
10.1007/s00330-011-2225-0
Published
2011-12-00
Epub
2011-00-25
Pages
2527-41
Language
English
Region
Germany
NLM ID
9114774
Subset
IM
External Links
PubMed source DOI: 10.1007/s00330-011-2225-0 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2